产品
编 号：F606216
分子式：C10H8N2OS
分子量：204.25
分子式：C10H8N2OS
分子量：204.25
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 62289-81-0
产品详情
生物活性：
SW106065 is an apoptosis inducer in malignant peripheral nerve sheath tumors (MPNST). SW106065 inhibits ATP consumption of sMPNST and other models of MPNST with an EC50 of 1 μM. SW106065 can be used for MPNST research.
体内研究：
SW106065 (Cpd21; 40 mg/kg; intraperitoneal injection; twice per day for 4 weeks) treatment can be delivered to mice in concentrations to sufficiently penetrate sMPNST tissue, and inhibit tumor development.Animal Model:NCR-nu/nu female mice (6-7 week old) injected with MPNST cells
Dosage:40 mg/kg
Administration:Intraperitoneal injection; twice per day for 4 weeks
Result:Reduced MPNST burden in a mouse allograft model.
体外研究：
SW106065 (Compound 21, Cpd21) inhibits the human MPNST cell lines growth in a dose-dependent manner, and EC50 concentrations of 439 nM and 753.6 nM for S462 and SNF96.2 cells, respectively. SW106065 remains nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts.SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment shows a decreased percentage of cells in S phase, and a corresponding increased percentage in G1/G0 and G2/M. SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment decreases the levels of cyclin A2, cyclin B1, cyclin D1, cyclin E, cdk4, and cdk6. And increases levels of cdkn1a and cdkn2a mRNA were observed in a dose-dependent manner.SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment decreases the levels of Cyclin D1 protein.SW106065 (Cpd21) treatment significant increase in the percentage of apoptotic cells.
SW106065 is an apoptosis inducer in malignant peripheral nerve sheath tumors (MPNST). SW106065 inhibits ATP consumption of sMPNST and other models of MPNST with an EC50 of 1 μM. SW106065 can be used for MPNST research.
体内研究：
SW106065 (Cpd21; 40 mg/kg; intraperitoneal injection; twice per day for 4 weeks) treatment can be delivered to mice in concentrations to sufficiently penetrate sMPNST tissue, and inhibit tumor development.Animal Model:NCR-nu/nu female mice (6-7 week old) injected with MPNST cells
Dosage:40 mg/kg
Administration:Intraperitoneal injection; twice per day for 4 weeks
Result:Reduced MPNST burden in a mouse allograft model.
体外研究：
SW106065 (Compound 21, Cpd21) inhibits the human MPNST cell lines growth in a dose-dependent manner, and EC50 concentrations of 439 nM and 753.6 nM for S462 and SNF96.2 cells, respectively. SW106065 remains nontoxic to normally dividing Schwann cells or mouse embryonic fibroblasts.SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment shows a decreased percentage of cells in S phase, and a corresponding increased percentage in G1/G0 and G2/M. SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment decreases the levels of cyclin A2, cyclin B1, cyclin D1, cyclin E, cdk4, and cdk6. And increases levels of cdkn1a and cdkn2a mRNA were observed in a dose-dependent manner.SW106065 (Cpd21; 0.25-5 μM; 24 hours; sMPNST cells) treatment decreases the levels of Cyclin D1 protein.SW106065 (Cpd21) treatment significant increase in the percentage of apoptotic cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备